There is a positive association between residential levels of air pollution and being diagnosed with dementia.
The burden of Alzheimer disease and related dementias (ADRD) is expected to increase to 3.3% in the United States by 2060.
In this cross-sectional study, the tau marker [18F]flortaucipir accurately distinguished Alzheimer Disease dementia from other non-AD neurodegenerative disorders about 90% of the time.
In this prospective cohort study, older patients with more optimal cardiovascular health metrics had a lower rate of developing dementia in a dose-dependent manner.
Despite the associated risk for death and cognitive decline, "off-label" prescribing of antipsychotics in patients with dementia has increased.
These data indicate that cortisol levels may contribute to the cognitive decline observed in elderly adults with late-life depression.
Administering the Visual Association Test improves the predictive value of the Mini-Mental State Examination score for dementia.
Patients with dementia had an increased prevalence of major depressive disorder.
These findings have high clinical relevance because patients with apathy are likely to withdraw from care.
In the previous SPRINT study, researchers compared an intensive BP reduction strategy (target systolic BP <120 mmHg) vs standard BP reduction strategy (target systolic BP <140 mmHg).
Patients who felt the situation was "abnormal" were less likely to seek help. This trend was more common in patients with Parkinson disease than patients with dementia, although both described feeling "embarrassed or ashamed."
Researchers of the DETECT study aim to assess the potential for future implementation of telemedicine consultation for managing neuropsychiatric symptoms in long-term care facilities.
Using the Visual Association Test along with the Mini Mental State Examination may improve predictive value to screen for cognitive deficits.
Given the frequent use of benzodiazepines among older people, even a small increase in absolute risk may be a serious matter on a population level.
The risk of dementia is increased in 50-year-olds with blood pressure ≥130 mm Hg, which is below the current threshold for hypertension.
Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.
The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.
There is a reduced risk for dementia for older Chinese adults actively participating in intellectual activities.
Public health strategies for preventing dementia should target socioeconomic gaps to reduce health disparities and protect the disadvantaged.
The researchers encouraged clinicians not to rely solely on medication to treat midlife anxiety, as benzodiazepines have been shown to increase mortality in certain groups; they pointed to talk therapy, meditation, and mindfulness-based interventions as possible considerations.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
Clinicians should take depression into careful consideration when treating patients with Alzheimer dementia, as the two conditions combined may predispose patients to cardiovascular disease more than either condition alone.
These findings indicate that anxiety may be a risk factor for late-life dementia, excluding anxiety that is related to prodromal cognitive decline.
These results suggest that antipsychotic exposure has no impact on relative mortality.
The use of certain anticholinergic drugs may increase the risk of future dementia.
Using hearing aids may slow cognitive decline in later life.
These data support the importance of TBI preventative measures and proper management strategies for subsequent dementia.
The findings also suggested that more a more recent diagnosis of psychosis was a greater predictor of the development of dementia, as opposed to cases where patients had been living with psychotic disorder diagnoses for 10 years or more.
Patients with a phonemic advantage at baseline should be followed more closely with a higher index of suspicion for progression to Alzheimer disease.
Researchers concluded that the partnership did not accelerate the overall decline in antipsychotic medication use among study participants.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- The Challenges of Identifying Biomarkers of Psychiatric Illness
- FDA Approves Powerful New Opioid Despite Criticisms
- Impulsivity in Bipolar Disorder, Borderline Personality Disorder, ADHD
- Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Updates in Borderline Personality Disorder: Your Questions Answered
- Violent Video Games Tied to Physical Aggression
- Shame Drives Suicidal Ideation Among Veterans With PTSD
- Long-term Healthy Diet Associated With Greater Hippocampal Volumes
- FDA to Ban Most Flavored Electronic Cigarettes
- Predictors of CBT Outcomes Identified in Youths With Anxiety Disorders
- Happy Childhood Memories Associated With Better Health
- FDA Launches MyStudies Mobile App in Effort to Increase Access to Real World Patient Data
- Heart Rate Variability Predicts Treatment Response in Anxious Depression